428847-12-5

Upstream product

• 536-90-3 m-Anisidine 
• 92-54-6 4-phenyl-1-piperazine 
• 1216002-27-5 3-bromo-N-(3-methoxyphenyl)propanamide 

Downstream Products

• 1610999-23-9 N-(3-methoxyphenyl)-N-[3-(4-phenylpiperazin-1-yl)propyl]propionamide 
• 1610999-24-0 3-methoxy-N-[3-(4-phenylpiperazin-1-yl)propyl]-N-propylaniline 
• 1610999-25-1 N-benzyl-3-methoxy-N-[3-(4-phenylpiperazin-1-yl)propyl]aniline 
• 1610999-26-2 3-methoxy-N-phenyl-N-[3-(4-phenylpiperazin-1-yl)propyl]aniline 
• 1610999-27-3 N-(3-methoxyphenyl)-N-[3-(4-phenylpiperazin-1-yl)propyl]benzenesulfonamide 
• 1610999-28-4 3-{[3-(4-phenylpiperazin-1-yl)propyl]propylamino}phenol 
• 1610999-29-5 3-{benzyl[3-(4-phenylpiperazin-1-yl)propyl]amino}phenol 
• 1610999-30-8 3-{phenyl[3-(4-phenylpiperazin-1-yl)propyl]amino}phenol 
• 1610999-31-9 N-(3-hydroxyphenyl)-N-[3-(4-phenylpiperazin-1-yl)propyl]benzenesulfonamide 
• 1610998-91-8 3-methoxy-N-[3-(4-phenylpiperazin-1-yl)propyl]aniline 
• 1610998-97-4 3-[3-(4-phenylpiperazin-1-yl)propylamino]phenol 

Relevant academic research and scientific papers

Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties

Many known 5-HT7 ligands contain either a serotonin-like or an arylpiperazine structure that, in published SAR studies, are generally supposed to bind the same receptor pocket. Conversely, we explored the hypothesis that two such moieties can c